Request Quote
Kenya
Key Features
- MOQ 10 CARTONS
- Disease-Modifying: Belimumab is designed to reduce the activity of systemic lupus erythematosus (SLE) by inhibiting B-cell activating factor (BAFF), a protein that promotes the survival of B cells involved in autoimmune responses.
- Improves Symptoms: Helps to decrease disease activity, reduce symptoms, and improve overall quality of life for patients with SLE.
- Flexible Administration: Available in both intravenous (IV) and subcutaneous (SC) forms, allowing for different treatment options based on patient needs and preferences.
Frequently bought together:
BENLYSTA is the first medicine approved to treat systemic lupus and adults with active lupus nephritis, an important treatment advance
Technical Details:
| UPC: | gsk-0000009 |
|---|---|
| Seller SKU: | gsk-0000009 |
| Condition: | New |
| Availability: | In Stock |
| Minimum order quantity: | 10 |
| Date first listed on Zandaux | Manufacturers | Suppliers & Exporters in Africa.: | Aug 30, 2024 |
BENLYSTA is the first medicine approved to treat systemic lupus and adults with active lupus nephritis, an important treatment advance
PRODUCT DESCRIPTION:
No reviews
Related Items
410
Active listings0
Items sold
